W
Wim H. A. Dokter
Researcher at Merck & Co.
Publications - 34
Citations - 1018
Wim H. A. Dokter is an academic researcher from Merck & Co.. The author has contributed to research in topics: Prednisolone & Insulin. The author has an hindex of 13, co-authored 28 publications receiving 841 citations. Previous affiliations of Wim H. A. Dokter include MSD Ignition & Schering-Plough.
Papers
More filters
Journal ArticleDOI
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Ronald Christiaan Elgersma,Ruud Coumans,Tijl Huijbregts,Wiro Michaël Petrus Bernardus Menge,John Joosten,Henri Johannes Spijker,Franciscus M. H. de Groot,Miranda M.C. van der Lee,Ruud Ubink,Diels van den Dobbelsteen,David F. Egging,Wim H. A. Dokter,GF Verheijden,Jacques M. Lemmens,C. Marco Timmers,Patrick Henry Beusker +15 more
TL;DR: This work sets out to develop a new class of linker-drugs based on duocarmycins, potent DNA-alkylating agents that are composed of a DNA-alksylating and aDNA-binding moiety and that bind into the minor groove of DNA.
Journal ArticleDOI
Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.
Daniël H. van Raalte,Valentina Nofrate,Mathijs C. Bunck,Thijs van Iersel,Jeroen Elassaiss Schaap,Ulla Nassander,Robert J. Heine,Andrea Mari,Wim H. A. Dokter,Michaela Diamant +9 more
TL;DR: Acute and short-term exposure to prednisolone impairs different aspects of beta-cell function, which contribute to its diabetogenic effects.
Journal ArticleDOI
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
Miranda M.C. van der Lee,Patrick G. Groothuis,Ruud Ubink,Monique van der Vleuten,Tanja van Achterberg,Eline Loosveld,Desiree Damming,Danielle Jacobs,Myrthe Rouwette,David F. Egging,Diels van den Dobbelsteen,Patrick Henry Beusker,Peter Goedings,GF Verheijden,Jacques M. Lemmens,Marco Timmers,Wim H. A. Dokter +16 more
TL;DR: In vivo antitumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models, whereas T-DM1 only showed significant antitumors activity in HER 2 3+ breast cancerPDX models.
Journal ArticleDOI
Preclinical profile of the HER2-targeting ADC SYD983/SYD985; introduction of a new duocarmycin-based linker-drug platform.
Wim H. A. Dokter,Ruud Ubink,Miranda van der Lee,Monique van der Vleuten,Tanja van Achterberg,Danielle Jacobs,Eline Loosveld,Diels van den Dobbelsteen,David F. Egging,Ellen Mattaar,Patrick Groothuis,Patrick Beusker,Ruud Coumans,Ronald Christiaan Elgersma,Wiro Michaël Petrus Bernardus Menge,John Joosten,Henri Johannes Spijker,Tijl Huijbregts,Vincent F.M.H. De Groot,Michel H.M. Eppink,Guy de Roo,Gijs Verheijden,Marco Timmers +22 more
TL;DR: Great potential is indicated for this new HER2-targeting ADC to become an effective drug for patients with Her2-positive cancers with a favorable safety profile and this new-generation duocarmycin-based linker-drug technology could be used with other mAbs to serve more indications in oncology.
Journal ArticleDOI
Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor
Raoul Frijters,Wilco W. M. Fleuren,Erik J M Toonen,Jan Tuckermann,Holger M. Reichardt,Hans van der Maaden,Andrea van Elsas,Marie-Jose van Lierop,Wim H. A. Dokter,Jacob de Vlieg,Jacob de Vlieg,Wynand Alkema +11 more
TL;DR: This study on prednisolone-induced effects in livers of WT and GRdim mice identified a number of interesting candidate genes and pathways regulated by GR dimers and sheds new light onto the complex transcriptional regulation of liver function by GCs.